Baseline characteristics
| . | BCMA CAR-T (n = 55) . |
|---|---|
| Demographics | |
| Age (y), median (range) | 62 (33-77) |
| Sex | |
| Female, n (%) | 28 (51) |
| Race | |
| White, n (%) | 36 (65) |
| Asian, n (%) | 5 (9) |
| African American, n (%) | 5 (9) |
| Other, n (%) | 9 (16) |
| Ethnicity | |
| Hispanic, n (%) | 8 (15) |
| Non-Hispanic, n (%) | 47 (85) |
| BMI, median (range) | 26.7 (20.5-56.2) |
| Charlson comorbidity index, median (range) | 2 (0-7) |
| MM diagnosis and type | |
| Time from diagnosis of MM (mo), median (range) | 6.8 (0.6-14.3) |
| Type of MM | |
| IgAĸ/IgAλ | 10 (18)/2 (4) |
| IgGĸ/IgGλ | 29 (53)/8 (15) |
| ĸ light chains | 5 (9) |
| IgDĸ | 1 (2) |
| Prior treatment | |
| Prior lines of therapy, median (range) | 6 (1-13) |
| Prior auto-transplant, n (%) | 48 (87) |
| Prior Allo-transplant, n (%) | 1 (2) |
| Time from transplant (mo), median (range) | 60.9 (4.6-146.9) |
| Prior McAb, n (%) | 49 (89) |
| Time from McAb (mo), median (range) | 7.0 (0.9-54.3) |
| Triple class refractory, n (%) | 49 (89) |
| Prior infections | |
| Hx of infection in 30 days before CAR-T, n (%) | 13 (24) |
| Baseline laboratory values | |
| Before LD | |
| IgG < 300 (mg/dL), n (%) | 23 (42) |
| ALC < 200 (cells/mm3), n (%) | 10 (18) |
| ANC < 500 (cells/mm3), n (%) | 1 (2) |
| Ferritin (μg/L), median (range) | 247 (29-5894) |
| Prior to CAR-T | |
| CD19 B cells absolute (×106cells/L), median (range) | 17.5 (1-537) |
| Treatment | |
| BC received, n (%) | 35 (64) |
| Type of BC, n (%) | |
| Cy-based | 24 (44) |
| Dexamethasone | 5 (40) |
| Carfilzomib or carfilzomib/Dex | 3 (5) |
| Dara/Pom/Dex | 1 (2) |
| Benda/Dex | 1 (2) |
| XRT | 1 (2) |
| BCMA CAR-T product, n (%) | |
| JCARH125 | 17 (31) |
| BB2121 | 23 (42) |
| BB21217 | 7 (13) |
| JNJ-4528 | 8 (15) |
| CAR-T dose (cells/kg), n (%) | |
| 600 × 106 | 6 (11) |
| 450 × 106 | 16 (29) |
| 300 × 106 | 22 (40) |
| 150 × 106 | 3 (5) |
| <100 × 106 | 8 (15) |
| Post–CAR-T characteristics | |
| Time to neutrophil recovery (days), median (range) | 8.5 (0-63.0) |
| Cytokine release syndrome (grade 1-2), n (%) | 48 (87) |
| Cytokine release syndrome (grade ≥ 3), n (%) | 0 (0) |
| Neurotoxicity (grade 1-2), n (%) | 6 (11) |
| Neurotoxicity (grade ≥ 3), n (%) | 2 (4) |
| Corticosteroids received, n (%) | 22 (40) |
| Tocilizumab received, n (%) | 42 (76) |
| Maximum ferritin level, median (range) | 1081 (32-40 000) |
| ICU admission by day 28, n (%) | 3 (5) |
| . | BCMA CAR-T (n = 55) . |
|---|---|
| Demographics | |
| Age (y), median (range) | 62 (33-77) |
| Sex | |
| Female, n (%) | 28 (51) |
| Race | |
| White, n (%) | 36 (65) |
| Asian, n (%) | 5 (9) |
| African American, n (%) | 5 (9) |
| Other, n (%) | 9 (16) |
| Ethnicity | |
| Hispanic, n (%) | 8 (15) |
| Non-Hispanic, n (%) | 47 (85) |
| BMI, median (range) | 26.7 (20.5-56.2) |
| Charlson comorbidity index, median (range) | 2 (0-7) |
| MM diagnosis and type | |
| Time from diagnosis of MM (mo), median (range) | 6.8 (0.6-14.3) |
| Type of MM | |
| IgAĸ/IgAλ | 10 (18)/2 (4) |
| IgGĸ/IgGλ | 29 (53)/8 (15) |
| ĸ light chains | 5 (9) |
| IgDĸ | 1 (2) |
| Prior treatment | |
| Prior lines of therapy, median (range) | 6 (1-13) |
| Prior auto-transplant, n (%) | 48 (87) |
| Prior Allo-transplant, n (%) | 1 (2) |
| Time from transplant (mo), median (range) | 60.9 (4.6-146.9) |
| Prior McAb, n (%) | 49 (89) |
| Time from McAb (mo), median (range) | 7.0 (0.9-54.3) |
| Triple class refractory, n (%) | 49 (89) |
| Prior infections | |
| Hx of infection in 30 days before CAR-T, n (%) | 13 (24) |
| Baseline laboratory values | |
| Before LD | |
| IgG < 300 (mg/dL), n (%) | 23 (42) |
| ALC < 200 (cells/mm3), n (%) | 10 (18) |
| ANC < 500 (cells/mm3), n (%) | 1 (2) |
| Ferritin (μg/L), median (range) | 247 (29-5894) |
| Prior to CAR-T | |
| CD19 B cells absolute (×106cells/L), median (range) | 17.5 (1-537) |
| Treatment | |
| BC received, n (%) | 35 (64) |
| Type of BC, n (%) | |
| Cy-based | 24 (44) |
| Dexamethasone | 5 (40) |
| Carfilzomib or carfilzomib/Dex | 3 (5) |
| Dara/Pom/Dex | 1 (2) |
| Benda/Dex | 1 (2) |
| XRT | 1 (2) |
| BCMA CAR-T product, n (%) | |
| JCARH125 | 17 (31) |
| BB2121 | 23 (42) |
| BB21217 | 7 (13) |
| JNJ-4528 | 8 (15) |
| CAR-T dose (cells/kg), n (%) | |
| 600 × 106 | 6 (11) |
| 450 × 106 | 16 (29) |
| 300 × 106 | 22 (40) |
| 150 × 106 | 3 (5) |
| <100 × 106 | 8 (15) |
| Post–CAR-T characteristics | |
| Time to neutrophil recovery (days), median (range) | 8.5 (0-63.0) |
| Cytokine release syndrome (grade 1-2), n (%) | 48 (87) |
| Cytokine release syndrome (grade ≥ 3), n (%) | 0 (0) |
| Neurotoxicity (grade 1-2), n (%) | 6 (11) |
| Neurotoxicity (grade ≥ 3), n (%) | 2 (4) |
| Corticosteroids received, n (%) | 22 (40) |
| Tocilizumab received, n (%) | 42 (76) |
| Maximum ferritin level, median (range) | 1081 (32-40 000) |
| ICU admission by day 28, n (%) | 3 (5) |
Allo, allogeneic; Auto, autologous; Hx, history.